(Q39066090)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28049357%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

title

Monoclonal antibodies: formulations of marketed products and recent advances in novel delivery system (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28049357%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28049357%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

author name string

Yanan Cui

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28049357%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Ping Cui

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28049357%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Binlong Chen

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28049357%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Hua Guan

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28049357%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

language of work or name

English

0 references

publication date

22 January 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28049357%20AND%20SRC:MED&resulttype=core&format=json

Drug Development and Industrial Pharmacy

5 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28049357%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

volume

43

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28049357%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28049357%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

page(s)

519-530

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28049357%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Clinical development success rates for investigational drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

What's fueling the biotech engine-2012 to 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

What's fueling the biotech engine-2011 to 2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Marketed therapeutic antibodies compendium

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Continuous cultures of fused cells secreting antibody of predefined specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Fully human antibodies from transgenic mouse and phage display platforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Molecular engineering and design of therapeutic antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

An overview on safety of monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Immunogenicity of protein therapeutics: The key causes, consequences and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Monoclonal antibodies: versatile platforms for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Antibody therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Antibody therapeutics in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

A review of advanced oral drug delivery technologies facilitating the protection and absorption of protein and peptide molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Advances in oral macromolecular drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Forced degradation studies of biopharmaceuticals: Selection of stress conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Protein drug stability: a formulation challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Accelerated formulation development of monoclonal antibodies (mAbs) and mAb-based modalities: review of methods and tools

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Liquid formulation for antibody drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Current and future issues in the manufacturing and development of monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Immunogenicity of therapeutic proteins: influence of aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Weak interactions govern the viscosity of concentrated antibody solutions: high-throughput analysis using the diffusion interaction parameter

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Assessing the Immunogenicity of Biopharmaceuticals

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Antibody structure, instability, and formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Molecular basis of high viscosity in concentrated antibody solutions: Strategies for high concentration drug product development

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Influence of pH, buffer species, and storage temperature on physicochemical stability of a humanized monoclonal antibody LA298.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

The effect of pH, hydrogen peroxide and temperature on the stability of human monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

pH-dependent antigen-binding antibodies as a novel therapeutic modality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Stabilization of proteins in solid form

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

The role of vitrification in anhydrobiosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Mechanisms of aggregate formation and carbohydrate excipient stabilization of lyophilized humanized monoclonal antibody formulations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Stability of buffer-free freeze-dried formulations: A feasibility study of a monoclonal antibody at high protein concentrations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

The relationship between protein aggregation and molecular mobility below the glass transition temperature of lyophilized formulations containing a monoclonal antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Effect of sorbitol and residual moisture on the stability of lyophilized antibodies: Implications for the mechanism of protein stabilization in the solid state.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Size and molecular flexibility of sugars determine the storage stability of freeze-dried proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Impact of sucrose level on storage stability of proteins in freeze-dried solids: I. Correlation of protein-sugar interaction with native structure preservation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Key interactions of surfactants in therapeutic protein formulations: A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Protection mechanism of Tween 80 during freeze-thawing of a model protein, LDH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

The effects of excipients on protein aggregation during agitation: an interfacial shear rheology study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Ionic strength affects tertiary structure and aggregation propensity of a monoclonal antibody adsorbed to silicone oil-water interfaces.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Renewal of the air-water interface as a critical system parameter of protein stability: aggregation of the human growth hormone and its prevention by surface-active compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Overview of recombinant human hyaluronidase-facilitated subcutaneous infusion of IgG in primary immunodeficiencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumato

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Viscosity of concentrated therapeutic protein compositions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Increasing IgG concentration modulates the conformational heterogeneity and bonding network that influence solution properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Characterizing Reversible Protein Association at Moderately High Concentration Via Composition-Gradient Static Light Scattering

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Establishing a link between amino acid sequences and self-associating and viscoelastic behavior of two closely related monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Impact of additives on the formation of protein aggregates and viscosity in concentrated protein solutions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Arginine and lysine reduce the high viscosity of serum albumin solutions for pharmaceutical injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Investigating high-concentration monoclonal antibody powder suspension in nonaqueous suspension vehicles for subcutaneous injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Novel strategies for the buccal delivery of macromolecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Recent advancements in mechanical reduction methods: particulate systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

PLGA-based nanoparticles: an overview of biomedical applications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

PLGA-nanoparticle mediated delivery of anti-OX40 monoclonal antibody enhances anti-tumor cytotoxic T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Optimized stability retention of a monoclonal antibody in the PLGA nanoparticles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Sustained cytoplasmic delivery and anti-viral effect of PLGA nanoparticles carrying a nucleic acid-hydrolyzing monoclonal antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

The protective effect of albumin on bevacizumab activity and stability in PLGA nanoparticles intended for retinal and choroidal neovascularization treatments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Self-associated submicron IgG1 particles for pulmonary delivery: effects of non-ionic surfactants on size, shape, stability, and aerosol performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Investigation of the stability and cellular uptake of self-associated monoclonal antibody (MAb) nanoparticles by non-small lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Characteristics and release profiles of MPEG-PCL-MPEG microspheres containing immunoglobulin G.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Stability study of full-length antibody (anti-TNF alpha) loaded PLGA microspheres

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Co-encapsulation of anti-BMP2 monoclonal antibody and mesenchymal stem cells in alginate microspheres for bone tissue engineering.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

EGF and curcumin co-encapsulated nanoparticle/hydrogel system as potent skin regeneration agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Development of ocular drug delivery systems using molecularly imprinted soft contact lenses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Hydrogels for protein delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Sustained release of Avastin® from polysaccharides cross-linked hydrogels for ocular drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Extended release of bevacizumab by thermosensitive biodegradable and biocompatible hydrogel

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Biocompatible reverse thermal gel sustains the release of intravitreal bevacizumab in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Light-activated, in situ forming gel for sustained suprachoroidal delivery of bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Sustained Release of a Monoclonal Antibody from Electrochemically Prepared Mesoporous Silicon Oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Protein-polyanion interactions for the controlled release of monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Pharmacokinetics, biocompatibility and bioavailability of a controlled release monoclonal antibody formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Antibody-mediated delivery of therapeutics for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

Nano spray drying: A novel method for preparing protein nanoparticles for protein therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03639045.2017.1278768

10.1080/03639045.2017.1278768

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28049357%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

1 reference